ERBB2 and metastatic malignant neoplasm in the lymph nodes: Although the first study on the relationship of HER2 expression with clinical outcomes is confounding, a meta-analysis has indicated that its expression is associated with tumor grade, lymph node metastasis, and poor prognosis in UCB [38].